AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16557151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pflex/LTV (low tidal volume 5-8 mL/kg PBW, PEEP set at Pflex + 2 cm H2O)
Number of subjects: 103
Study 16557151 — intervention group
Group type: COMPARATOR
Intervention: Control (tidal volume 9-11 mL/kg PBW, PEEP >= 5 cm H2O)
Number of subjects: 103
Study 16557151 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 103
Study 15121371 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 46
Study 15121371 — intervention group
Group type: COMPARATOR
Intervention: Placebo and laser treatment
Number of subjects: 46
Study 11336589 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial agents
Number of subjects: 0
Study 11336589 — intervention group
Group type: EXPERIMENTAL
Intervention: New antimicrobial compounds
Number of subjects: 0
Study 9805220 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of red wine
Number of subjects: 9
Study 9805220 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of malt whisky
Number of subjects: 9
Study 9805220 — intervention group
Group type: COMPARATOR
Intervention: Unmatured 'new make' spirit
Number of subjects: 9
Study 8301543 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/70 kg morphine
Number of subjects: 12
Study 8301543 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/70 kg morphine
Number of subjects: 12
Study 8301543 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/70 kg morphine
Number of subjects: 12
Study 8301543 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg morphine
Number of subjects: 12
Study 2899239 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (28 mg)
Number of subjects: 0
Study 2899239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2899239 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (14 mg)
Number of subjects: 0
Study 2899239 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide
Number of subjects: 0
Study 2899239 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral frusemide (20 mg)
Number of subjects: 0
Study 29059442 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives ($15-$35 rewards for brief smoking abstinence)
Number of subjects: 50
Study 29059442 — intervention group
Group type: COMPARATOR
Intervention: Control group ($10 at each assessment regardless of abstinence)
Number of subjects: 50
Study 29276227 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Current (CC) system
Number of subjects: 20
Study 29276227 — intervention group
Group type: COMPARATOR
Intervention: Constant Voltage (CV) system
Number of subjects: 20
Study 26599247 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSure Sealant
Number of subjects: 1
Study 23181989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing forty times per portion
Number of subjects: 21
Study 23181989 — intervention group
Group type: COMPARATOR
Intervention: Chewing fifteen times per portion
Number of subjects: 21
Study 22010808 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOL intervention (N = 1,695)
Number of subjects: 3311
Study 22010808 — intervention group
Group type: COMPARATOR
Intervention: Control condition (N = 1,616)
Number of subjects: 3311
Study 22010808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CPOL intervention and control
Number of subjects: 3311
Study 18297290 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX-A) injections at different doses
Number of subjects: 150
Study 18297290 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 16847080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 45
Study 16847080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14564313 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day in addition to HMG-CoA reductase inhibitor
Number of subjects: 15000
Study 14564313 — intervention group
Group type: COMPARATOR
Intervention: HMG-CoA reductase inhibitor
Number of subjects: 15000
Study 11091245 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusion with subsequent development of postoperative infectious complications
Number of subjects: 740
Study 11091245 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusion without subsequent infection
Number of subjects: 740
Study 11091245 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative infectious complications without preceding transfusion
Number of subjects: 740
Study 11091245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of blood transfusion and subsequent development of infection
Number of subjects: 740
Study 11091245 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 740
Study 11091245 — intervention group
Group type: COMPARATOR
Intervention: Transfused patients
Number of subjects: 740
Study 9069566 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 6847
Study 9069566 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes mellitus (NIDDM)
Number of subjects: 6847
Study 9069566 — intervention group
Group type: COMPARATOR
Intervention: Age association with IGT
Number of subjects: 6847
Study 9069566 — intervention group
Group type: COMPARATOR
Intervention: Age association with NIDDM
Number of subjects: 6847
Study 9069566 — intervention group
Group type: COMPARATOR
Intervention: BMI association with IGT
Number of subjects: 6847
Study 9069566 — intervention group
Group type: COMPARATOR
Intervention: BMI association with NIDDM
Number of subjects: 6847
Study 9069566 — intervention group
Group type: COMPARATOR
Intervention: Height association with NIDDM
Number of subjects: 6847
Study 9069566 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression analysis
Number of subjects: 6847
Study 8349904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-education (written explanation of the need for full body skin examination)
Number of subjects: 286
Study 8349904 — intervention group
Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 286
Study 3568020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass screening for breast cancer
Number of subjects: 0
Study 3568020 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 0
Study 31367914 — intervention group
Group type: EXPERIMENTAL
Intervention: F-100
Number of subjects: 153
Study 31367914 — intervention group
Group type: EXPERIMENTAL
Intervention: F-100D
Number of subjects: 153
Study 31367914 — intervention group
Group type: COMPARATOR
Intervention: IF
Number of subjects: 153
Study 29532297 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated notification system for finalized TPADs via email
Number of subjects: 253
Study 29532297 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no automated notification)
Number of subjects: 253
Study 29532297 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated notification system for finalized TPADs via email (sub-group analysis)
Number of subjects: 253
Study 29532297 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no automated notification) (sub-group analysis)
Number of subjects: 253
Study 26028361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g amino acids/(kg·d) plus 2 g lipids/(kg·d)
Number of subjects: 28
Study 26028361 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g amino acids/(kg·d) plus 2 g lipids/(kg·d)
Number of subjects: 28
Study 26028361 — intervention group
Group type: COMPARATOR
Intervention: 2.4 g amino acids/(kg·d) (control group)
Number of subjects: 28
Study 24448121 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 70
Study 24448121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22512461 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus systemic amoxicillin + metronidazole (SMA)
Number of subjects: 187
Study 22512461 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus periodontal surgery (SURG)
Number of subjects: 187
Study 22512461 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus local tetracycline delivery (LTC)
Number of subjects: 187
Study 22512461 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus no adjunctive treatment
Number of subjects: 187
Study 19680275 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge MIVS
Number of subjects: 85
Study 19680275 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-gauge MIVS
Number of subjects: 85
Study 17970791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 344
Study 17970791 — intervention group
Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 344
Study 15840990 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 100
Study 15840990 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 100
Study 15840990 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg
Number of subjects: 100
Study 15840990 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 100
Study 15840990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12809960 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg TID
Number of subjects: 99
Study 12809960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/d
Number of subjects: 99
Study 12809960 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg TID with Fluvastatin 80 mg/d
Number of subjects: 99
Study 12809960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 11034935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 19768
Study 8674343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (32 degrees C for 24 hrs)
Number of subjects: 15
Study 8674343 — intervention group
Group type: COMPARATOR
Intervention: Normothermic treatment group
Number of subjects: 15
Study 8674343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid nitrite and nitrate concentrations
Number of subjects: 15
Study 8674343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral blood flow
Number of subjects: 15
Study 8674343 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterio‐jugular oxygen content difference
Number of subjects: 15
Study 8674343 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma nitrite and nitrate concentrations
Number of subjects: 15
Study 8674343 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Severity Score
Number of subjects: 15
Study 1797999 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 0
Study 1797999 — intervention group
Group type: EXPERIMENTAL
Intervention: White-coat hypertension
Number of subjects: 0
Study 6409627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% of energy)
Number of subjects: 12
Study 6409627 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (45% of energy)
Number of subjects: 12
Study 6409627 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in polyunsaturated fatty acids
Number of subjects: 12
Study 6409627 — intervention group
Group type: COMPARATOR
Intervention: Diet high in saturated fatty acids
Number of subjects: 12
Study 30608337 — intervention group
Group type: EXPERIMENTAL
Intervention: Maggot therapy (MT)
Number of subjects: 50
Study 28067068 — intervention group
Group type: EXPERIMENTAL
Intervention: Special examination gown + nature-based sounds
Number of subjects: 120
Study 28067068 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special gown or sounds)
Number of subjects: 120
Study 27253669 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral contraceptive pill (OCP)
Number of subjects: 0
Study 27253669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 0
Study 27253669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (OCP + Intensive lifestyle intervention)
Number of subjects: 0
Study 27253669 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 24297663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg/day
Number of subjects: 18
Study 23207332 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFNa-2a for 72 weeks
Number of subjects: 86
Study 23207332 — intervention group
Group type: COMPARATOR
Intervention: Peg-IFNa-2a for 48 weeks
Number of subjects: 86
Study 20709087 — intervention group
Group type: EXPERIMENTAL
Intervention: 800ml of paper filtered coffee daily for 5 days
Number of subjects: 38
Study 20709087 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 38
Study 17383912 — intervention group
Group type: COMPARATOR
Intervention: Normal saline drops before and after surgery (Group A)
Number of subjects: 88
Study 17383912 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline drops before and tetracaine 1% drops after surgery (Group B)
Number of subjects: 88
Study 17383912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 1% drops before and after surgery (Group C)
Number of subjects: 88
Study 16350716 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 3 x 120mg a day with a 1000-1200 kcal/day balanced diet and regular physical exercises
Number of subjects: 20
Study 16350716 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women, mean age 53.5 ± 5.4 yrs, BMI 24.1 ± 2.2 kg/m2)
Number of subjects: 20
Study 12062881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose haloperidol (mean dose 5.0 mg at 6 months)
Number of subjects: 62
Study 12062881 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (mean dose 6.0 mg at 6 months)
Number of subjects: 62
Study 10552264 — intervention group
Group type: EXPERIMENTAL
Intervention: Face skin cooling (FaC)
Number of subjects: 7
Study 10552264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cooling (CoC)
Number of subjects: 7
Study 10552264 — intervention group
Group type: COMPARATOR
Intervention: Cool air breathing (CAB)
Number of subjects: 7
Study 9088582 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 12
Study 9088582 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 12
Study 9088582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9088582 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan single dose 10 mg
Number of subjects: 12
Study 1300759 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (15% decrease in total caloricity, 30% reduction in fat, 9% reduction in carbohydrates)
Number of subjects: 108
Study 1300759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 108
Study 3889100 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg twice daily
Number of subjects: 301
Study 29671353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception after 3 months (T2)
Number of subjects: 431
Study 29671353 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variations in HRQOL
Number of subjects: 431
Study 27552275 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate offer of genetic counseling
Number of subjects: 102
Study 27552275 — intervention group
Group type: COMPARATOR
Intervention: Mailed brochure on how to obtain counseling
Number of subjects: 102
Study 24518169 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insulin treatment
Number of subjects: 283
Study 22406658 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 55
Study 22406658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 22406658 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol No-Shock Expectation
Number of subjects: 55
Study 19812926 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate tissue adhesive for final layer closure of the skin (44 children)
Number of subjects: 90
Study 19812926 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable one-on-one single skin sutures (46 children)
Number of subjects: 90
Study 18180864 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine added to current oral antidiabetic drugs (OAD) regimen
Number of subjects: 55
Study 18180864 — intervention group
Group type: COMPARATOR
Intervention: Increased dosage of oral antidiabetic drugs (OAD)
Number of subjects: 55
Study 15858073 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonics treatment package
Number of subjects: 0
Study 12650495 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block with 5 mL 0.5% bupivacaine with epinephrine
Number of subjects: 60
Study 12650495 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam patch (48 mg) applied to each shoulder
Number of subjects: 60
Study 12650495 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study 10792383 — intervention group
Group type: COMPARATOR
Intervention: HAART (n = 6)
Number of subjects: 22
Study 10792383 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus low dose rIL-2 (1000 000 U/daily) (n = 8)
Number of subjects: 22
Study 10792383 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus rIL-2 after granulocyte colony-stimulating factor (n = 8)
Number of subjects: 22
Study 8680492 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injector for morphine (8 mg, 5 mg if weight ≤ 65 kg)
Number of subjects: 59
Study 8680492 — intervention group
Group type: COMPARATOR
Intervention: Needle and syringe for morphine (8 mg, 5 mg if weight ≤ 65 kg)
Number of subjects: 59
Study 8680492 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injector for heparin (3500 U every 8 hours for 5 days)
Number of subjects: 59
Study 8680492 — intervention group
Group type: COMPARATOR
Intervention: Needle and syringe for heparin (3500 U every 8 hours for 5 days)
Number of subjects: 59
Study 1847278 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (100 micrograms/kg)
Number of subjects: 52
Study 1847278 — intervention group
Group type: COMPARATOR
Intervention: Pipecuronium (80 micrograms/kg)
Number of subjects: 52
Study 1847278 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg) plus Pancuronium (100 micrograms/kg)
Number of subjects: 52
Study 1847278 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg) plus Pipecuronium (80 micrograms/kg)
Number of subjects: 52
Study 1847278 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (pancuronium and pipecuronium)
Number of subjects: 52
Study 30327777 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecure households
Number of subjects: 696
Study 30327777 — intervention group
Group type: COMPARATOR
Intervention: Food secure households
Number of subjects: 696
Study 30327777 — intervention group
Group type: EXPERIMENTAL
Intervention: Age range 30-39
Number of subjects: 696
Study 30327777 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with 10 or more years age difference with their husband
Number of subjects: 696
Study 30327777 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with high decision-making power
Number of subjects: 696
Study 26890244 — intervention group
Group type: EXPERIMENTAL
Intervention: Live High-Train Low (LHTL) training (n=10)
Number of subjects: 16
Study 26890244 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (n=6)
Number of subjects: 16
Study 26890244 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolumic hemodilution
Number of subjects: 16
Study 26890244 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise (both groups)
Number of subjects: 16
Study 26890244 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise after isovolumic hemodilution
Number of subjects: 16
Study 24759327 — intervention group
Group type: EXPERIMENTAL
Intervention: Melimine-coated lenses
Number of subjects: 0
Study 24759327 — intervention group
Group type: COMPARATOR
Intervention: Uncoated lenses
Number of subjects: 0
Study 23270288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel II appliance treatment for 1 year 11 months
Number of subjects: 25
Study 23270288 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects in Class II division 1)
Number of subjects: 25
Study 20231536 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 1549
Study 20231536 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan
Number of subjects: 1549
Study 20231536 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of ramipril and telmisartan
Number of subjects: 1549
Study 20231536 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1549
Study 18318974 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Patients Programme self-management course
Number of subjects: 629
Study 15883418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum low-glycemic load diet
Number of subjects: 23
Study 15883418 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-fat diet
Number of subjects: 23
Study 12645641 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 12645641 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 12645641 — intervention group
Group type: COMPARATOR
Intervention: Surgical approach (CABG)
Number of subjects: 0
Study 12645641 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive approach including PCI
Number of subjects: 0
Study 12645641 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy only
Number of subjects: 0
Study 12645641 — intervention group
Group type: EXPERIMENTAL
Intervention: New devices (thrombectomy devices, drug-eluting stents)
Number of subjects: 0
Study 10484395 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rectal distension
Number of subjects: 10
Study 10484395 — intervention group
Group type: COMPARATOR
Intervention: Sham rectal distension
Number of subjects: 10
Study 9139277 — intervention group
Group type: COMPARATOR
Intervention: Responsive patients (on one or two drugs)
Number of subjects: 299